Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

162 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Genetic markers and phosphoprotein forms of beta-catenin pβ-Cat552 and pβ-Cat675 are prognostic biomarkers of cervical cancer.
Scholl SM, Beal J, de Koning L, Girard E, Popovic M, de la Rochefordière A, Lecuru F, Fourchotte V, Ngo C, Floquet A, Berns EM, Kenter G, Gestraud P, von der Leyen H, Lecerf C, Puard V, Roman SR, Latouche A, Kereszt A, Balint B, Rouzier R, Kamal M. Scholl SM, et al. Among authors: floquet a. EBioMedicine. 2020 Nov;61:103049. doi: 10.1016/j.ebiom.2020.103049. Epub 2020 Oct 20. EBioMedicine. 2020. PMID: 33096476 Free PMC article.
Olaparib First-Line Maintenance Monotherapy in BRCA-Mutated Epithelial Ovarian Cancer: Descriptive Analysis of the First French Real-World Data Study.
Bellier C, Gladieff L, Le Du F, Berton D, Bonnard C, Suau D, Richard AC, Brenner O, Lahouegue A, Freyer G, Floquet A, Frank S, Kfoury M. Bellier C, et al. Among authors: floquet a. Drugs Real World Outcomes. 2023 Jun;10(2):207-213. doi: 10.1007/s40801-022-00349-9. Epub 2023 Jan 11. Drugs Real World Outcomes. 2023. PMID: 36630055 Free PMC article.
Efficacy of chemotherapy according to BRCA status in patients with high-grade serous ovarian carcinoma at first platinum-sensitive relapse.
Brouillard-Saby F, Saint-Martin C, Ray-Coquard I, Gladieff L, Pomel C, Colombo PE, Classe JM, Chevrier M, Joly F, De la Motte Rouge T, Floquet A, Sabatier R, Barranger E, Costaz H, Leblanc E, Marchal F, Pautier P, Bosquet L, Rodrigues M. Brouillard-Saby F, et al. Among authors: floquet a. Int J Gynecol Cancer. 2023 Apr 3;33(4):577-584. doi: 10.1136/ijgc-2022-003993. Int J Gynecol Cancer. 2023. PMID: 36631150
PIK3CA Pathway Mutations Predictive of Poor Response Following Standard Radiochemotherapy ± Cetuximab in Cervical Cancer Patients.
de la Rochefordiere A, Kamal M, Floquet A, Thomas L, Petrow P, Petit T, Pop M, Fabbro M, Kerr C, Joly F, Sevin E, Maillard S, Curé H, Weber B, Brunaud C, Minsat M, Gonzague L, Berton-Rigaud D, Aumont M, Gladieff L, Peignaux K, Bernard V, Leroy Q, Bieche I, Margogne A, Nadan A, Fourchotte V, Diallo A, Asselain B, Plancher C, Armanet S, Beuzeboc P, Scholl SM. de la Rochefordiere A, et al. Among authors: floquet a. Clin Cancer Res. 2015 Jun 1;21(11):2530-7. doi: 10.1158/1078-0432.CCR-14-2368. Epub 2015 Feb 27. Clin Cancer Res. 2015. PMID: 25724520 Clinical Trial.
Epidermal Growth Factor Receptor (EGFR) Pathway Biomarkers in the Randomized Phase III Trial of Erlotinib Versus Observation in Ovarian Cancer Patients with No Evidence of Disease Progression after First-Line Platinum-Based Chemotherapy.
Despierre E, Vergote I, Anderson R, Coens C, Katsaros D, Hirsch FR, Boeckx B, Varella-Garcia M, Ferrero A, Ray-Coquard I, Berns EM, Casado A, Lambrechts D, Jimeno A; European Organisation for Research and Treatment of Cancer-Gynaecological Cancer Group (EORTC-GCG); Groupe d’Investigateurs Nationaux pour les Etudes des Cancers de l’Ovaire (GINECO); Austrian Arbeitsgemeinschaft für Gynäkologische Onkologie (A-AGO); National Cancer Research Institute (NCRI); Australia New Zealand Gynaecological Oncology Group (ANZGOG); Mario Negri Gynecologic Oncology group (MaNGO). Despierre E, et al. Target Oncol. 2015 Dec;10(4):583-96. doi: 10.1007/s11523-015-0369-6. Target Oncol. 2015. PMID: 26004768 Free PMC article. Clinical Trial.
Efficacy and safety of bevacizumab-containing neoadjuvant therapy followed by interval debulking surgery in advanced ovarian cancer: Results from the ANTHALYA trial.
Rouzier R, Gouy S, Selle F, Lambaudie E, Floquet A, Fourchotte V, Pomel C, Colombo PE, Kalbacher E, Martin-Francoise S, Fauvet R, Follana P, Lesoin A, Lecuru F, Ghazi Y, Dupin J, Chereau E, Zohar S, Cottu P, Joly F. Rouzier R, et al. Among authors: floquet a. Eur J Cancer. 2017 Jan;70:133-142. doi: 10.1016/j.ejca.2016.09.036. Epub 2016 Dec 1. Eur J Cancer. 2017. PMID: 27914243 Free article. Clinical Trial.
Clinical and genetic landscape of treatment naive cervical cancer: Alterations in PIK3CA and in epigenetic modulators associated with sub-optimal outcome.
Scholl S, Popovic M, de la Rochefordiere A, Girard E, Dureau S, Mandic A, Koprivsek K, Samet N, Craina M, Margan M, Samuels S, Zijlmans H, Kenter G, Hillemanns P, Dema S, Dema A, Malenkovic G, Djuran B, Floquet A, Garbay D, Guyon F, Colombo PE, Fabbro M, Kerr C, Ngo C, Lecuru F, Campo ERD, Coutant C, Marchal F, Mesgouez-Nebout N, Fourchotte V, Feron JG, Morice P, Deutsch E, Wimberger P, Classe JM, Gleeson N, von der Leyen H, Minsat M, Dubot C, Gestraud P, Kereszt A, Nagy I, Balint B, Berns E, Jordanova E, Saint-Jorre N, Savignoni A, Servant N, Hupe P, de Koning L, Fumoleau P, Rouzier R, Kamal M. Scholl S, et al. Among authors: floquet a. EBioMedicine. 2019 May;43:253-260. doi: 10.1016/j.ebiom.2019.03.069. Epub 2019 Apr 2. EBioMedicine. 2019. PMID: 30952619 Free PMC article.
Corrigendum to 'clinical and genetic landscape of treatment naive cervical cancer: Alterations in PIK3CA and in epigenetic modulators associated with sub-optimal outcome'.
Scholl S, Popovic M, Rochefordiere A, Girard E, Dureau S, Mandic A, Koprivsek K, Samet N, Craina M, Margan M, Samuels S, Zijlmans H, Kenter G, Hillemanns P, Dema S, Dema A, Malenkovic G, Djuran B, Floquet A, Garbay D, Guyon F, Colombo PE, Fabbro M, Kerr C, Ngo C, Lecuru F, Del Campo ER, Coutant C, Marchal F, Mesgouez-Nebout N, Fourchotte V, Feron JG, Morice P, Deutsch E, Wimberger P, Classe JM, Gleeson N, Leyen HV, Minsat M, Dubot C, Gestraud P, Kereszt A, Nagy I, Balint B, Berns E, Jordanova E, de Saint-Jorre N, Savignoni A, Servant N, Hupe P, de Koning L, Fumoleau P, Rouzier R, Kamal M. Scholl S, et al. Among authors: floquet a. EBioMedicine. 2020 Jul;57:102875. doi: 10.1016/j.ebiom.2020.102875. Epub 2020 Jul 7. EBioMedicine. 2020. PMID: 32650273 Free PMC article. No abstract available.
Human papilloma virus (HPV) integration signature in Cervical Cancer: identification of MACROD2 gene as HPV hot spot integration site.
Kamal M, Lameiras S, Deloger M, Morel A, Vacher S, Lecerf C, Dupain C, Jeannot E, Girard E, Baulande S, Dubot C, Kenter G, Jordanova ES, Berns EMJJ, Bataillon G, Popovic M, Rouzier R, Cacheux W, Le Tourneau C, Nicolas A, Servant N, Scholl SM, Bièche I; RAIDs Consortium. Kamal M, et al. Br J Cancer. 2021 Feb;124(4):777-785. doi: 10.1038/s41416-020-01153-4. Epub 2020 Nov 16. Br J Cancer. 2021. PMID: 33191407 Free PMC article.
Surgical Implications of Advanced Low-Grade Serous Ovarian Cancer: Analysis of the Database of the Tumeurs Malignes Rares Gynécologiques Network.
Bonsang-Kitzis H, Panchbhaya N, Bats AS, Pujade-Lauraine E, Pautier P, Ngô C, Le Frère-Belda MA, Kalbacher E, Floquet A, Berton-Rigaud D, Lefeuvre-Plesse C, Fabbro M, Ray-Coquard I, Lécuru F. Bonsang-Kitzis H, et al. Among authors: floquet a. Cancers (Basel). 2022 May 9;14(9):2345. doi: 10.3390/cancers14092345. Cancers (Basel). 2022. PMID: 35565475 Free PMC article.
162 results